Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes

Area of Science:

• Pharmacology and Endocrinology
• Biotechnology and Pharmaceutical Manufacturing
• Regulatory Science

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are key for type 2 diabetes mellitus (T2DM) and obesity management.
• Semaglutide, a long-acting GLP-1 RA, shows significant metabolic and cardiovascular benefits.
• Interest is growing in synthetic peptide versions of GLP-1 RAs due to cost considerations.

Purpose of the Study:

• To review the development of semaglutide.
• To examine global regulatory perspectives on synthetic versus recombinant peptide production.
• To explore clinical implications of manufacturing variability and therapeutic potential beyond T2DM and obesity.

Main Methods:

• Narrative review sourcing articles from PubMed, Scopus, and Google Scholar.
• Analysis of regulatory frameworks in the EU, US, and India for peptide therapeutics.
• Discussion of manufacturing process impacts on impurity profiles, stability, and immunogenicity.

Main Results:

• Regulatory pathways for synthetic peptides differ globally, with India employing a risk-based approach.
• Manufacturing processes significantly impact peptide quality attributes, influencing clinical outcomes.
• Demonstrating quality and clinical comparability is crucial for approving follow-on semaglutide versions.

Conclusions:

• The shift from recombinant to synthetic peptide production necessitates rigorous evaluation.
• Ensuring quality and clinical comparability is paramount for regulatory approval of generic semaglutide.
• Semaglutide holds expanding therapeutic promise for various metabolic conditions.